Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Chemistry Department expands its international footprint
2015-10-14

Prof André Roodt

Prof André Roodt from the Department of Chemistry at the University of the Free State has returned from a research visit at the St Petersburg State University in Russia. The research he conducted at the St Petersburg State University is part of a bilateral collaboration agreement between the University of the Free State and St Petersburg State University.

As part of his visit to Russia (from 17 to 28 September 2015), Prof Roodt presented a seminar at St Petersburg State University, and a lecture at the conference titled: International conference on Organometallic and Coordination Chemistry: Achievements and Challenges.

One of the local Russian newspapers quoted Prof Roodt as “world-renowned expert in the study of chemical kinetics and mechanisms of chemical reactions”. His presentation: Are detailed reaction mechanisms really necessary in (applied) organometallic and coordination chemistry' attracted great interest from the St Petersburg chemists.

The bilateral agreement came to life a year ago when the St Petersburg State University chemists won a grant in a competition to create an international research group, the International Laboratory of Organometallic Chemistry. The Laboratory is headed by Prof Vadim Kukushkin of the St Petersburg State University.

In addition to the employees of St Petersburg University, the research group consists of researchers from Portugal, Finland, South Africa, and Azerbaijan. Together, these groups of scientists are working on the problem of non-reactive metal activation molecules. The main theme of the research laboratory is in the catalysis and activation of metal inert molecules which then undergo significant change, and become meaningful to people chemicals, such as drugs.

As part of this initiative, a bilateral collaboration agreement exists between the St Petersburg State University and the UFS (Russian Science Foundation grant 14-43-00017). Students from our university have visited and conducted research at the St Petersburg State University while some of their students visit and research reaction kinetics at the UFS.

Prof Roodt hosted Valeria Burianova, a student from the St Petersburg University. During her visit at the UFS, she learned about response kinetics. A UFS PhD student, Carla Pretorius, joined the group in Russia where she conducted research on the intermetallic rhodium-rhodium interactions for the formation of nano-wires and -plates, with applications in the micro-electronics industry, and a  potential for harvesting sun energy.

The UFS Department of Chemistry extended its international footprint further with three of its students, Mampotsu Tsosane, Petrus Mokolokolo, and Tom Kama, returning from Switzerland after a six-week research visit in the group of Prof Roger Alberto from the University of Zürich. In return, Prof Roodt hosted a Swiss PhD student, Angelo Frei from Zürich, and taught him more about reaction mechanisms.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept